CUMBERLAND PHARMACEUTICALS INC(CPIX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

CUMBERLAND PHARMACEUTICALS INC (CPIX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CPIX at 20.1/100 on a 32-signal composite quality model, placing it at rank #2,784 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (5.5) and revenue growth (8.5), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), CUMBERLAND PHARMACEUTICALS INC reports quarterly revenue of $166.5K, net income of $-4.3M, free cash flow of $130.5K. Top institutional holders of CPIX by reported 13-F value include Ikarian Capital, RENAISSANCE TECHNOLOGIES, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CPIX trades on the Nasdaq exchange and files with the SEC under CIK 1087294. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CPIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CUMBERLAND PHARMACEUTICALS INC directly from SEC EDGAR.